HITECK (300683.SZ) Latest News & Headlines

Weekly Recap | Zai Lab +0.58%, most brokers rate it buy

Weekly Review·Sep 5 at 08:27 AM

- Zai Lab cumulative weekly stock price rose 0.58 % to close at 26.23 dollars, outperforming the S & P 500. - A total of 12 institutions provided ratings with a consensus target price of 33.14 dollars, reflecting a significant valuation divergence ranging from 24.25 dollars to 50.00 dollars. - The company released no new announcements during the week, while market focus centered on VYVGART Hytrulo product data and subsequent capital revaluation trends.

ZLAB-3.75%

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn·Apr 7 at 01:41 AM

512290-1.57%002038-2.71%

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

Wallstreetcn·Mar 31 at 08:37 AM

002821-1.55%002361+1.78%

The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declines

Wallstreetcn·Mar 19 at 06:30 AM

300016-5.23%688136-4.20%

The A-share innovative drug concept continues to be strong, with YABAO PHARM.CORP hitting the limit up, and JENKEM, HSGC, YKYY, MEDISAN, HITECK, and others leading in gains

Wallstreetcn·Jul 24, 2025 at 01:32 AM

600351-2.46%688356-4.23%